Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Rivoceranib Formulations in Healthy Subjects
NCT05287360Phase 1Completed
- Sponsor
- Elevar Therapeutics
- Start
- Dec 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Rivoceranib in gastric cancer (GC) and hepatocellular carcinoma (HCC) (4 arms), sponsored by Elevar Therapeutics. Primary endpoints: Area Under The Concentration-time Curve From Time 0 To The Last Observed Non-zero Concentration, Area Under The Concentration-time Curve From Time 0 Extrapolated To Infinity and 1 more. Started Dec 2021; status: completed.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05287360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05287360.